- Not yet recruiting
NCT05552976: Phase 3: CC-92480 + Carfilzomib-dex (480Kd) Vs Carfilzomib-dex (Kd) RRMM (SUCCESSOR-2)
Updated: Sep 30, 2022
(SUCCESSOR-2)
CC-92480 - Mezi - Mezigdomide - CELMoD
NCT05552976: Phase 3: A Study to Evaluate CC-92480 in Combination With Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (SUCCESSOR-2)
NCT05552976: Phase 3: A Study to Evaluate CC-92480 in Combination With Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (SUCCESSOR-2)
The purpose of the study is to compare CC-92480 (BMS-986348) with carfilzomib and dexamethasone (480Kd) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM.
Sponsor
ClinicalTrials.gov Identifier: NCT05552976
Official Title: A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
First Posted : September 23, 2022
Click here for details on ClinicalTrials.gov
cereblon E3 ubiquitin ligase modulating agent CC-92480
Mezigdomide (Code C146660)
CC 92480
CC-92480
CELMoD CC-92480
Cereblon E3 Ligase Modulation Drug CC-92480
Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480
Cereblon Modulator CC-92480
Mezigdomide
MEZIGDOMIDE
Drug: CC-92480
Drug: Carfilzomib
Locations
United States, Ohio
United States, South Carolina
Argentina
Australia, Queensland
Australia, Victoria
Australia
Europe
Asia
China, Beijing
China, Fujian
China, Guangdong
China, Hunan
China, Jiangsu
China, Jilin
China, Liaoning
China, Shaanxi
China, Shandong
China, Shanghai
China, Tianjin
China, Yunnan
China, Zhejiang
China
Colombia
Germany
Hong Kong
India
Singapore
Taiwan
RELATED POSTS
NCT05519085: Phase 3: (SUCCESSOR-1) CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM
NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma
NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma
